ex scientia, Sunovion partner for new medicines to treat psychiatric disorders
Under the new $4.8m strategic alliance, ex scientia received an upfront payment of $1m. As part of the deal, Sunovion will receive exclusive worldwide rights to the resulting
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.